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Psoriasis, which is regarded as a T-cell-mediated chronic inflammatory skin disease, is
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characterized by hyperproliferation and poor differentiation of epidermal keratinocytes. In
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this study, we aimed to determine the in vivo effect of a potentially probiotic strain,
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Lactobacillus pentosus GMNL-77, in imiquimod-induced epidermal hyperplasia and
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psoriasis-like skin inflammation in BALB/c mice. Oral administration of L. pentosus GMNL-
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77 significantly decreased erythematous scaling lesions. Real-time polymerase chain reaction showed that treatment with L. pentosus GMNL-77 significantly decreased the mRNA

Keywords:

levels of proinflammatory cytokines, including tumor necrosis factor-alpha, interleukin

cytokines

(IL)-6, and the IL-23/IL-17A axis-associated cytokines (IL-23, IL-17A/F, and IL-22) in the skin

imiquimod

of imiquimod-treated mice. In addition, we found that L. pentosus GMNL-77 decreased the

inflammation

spleen weights of the imiquimod-treated group and reduced the numbers of IL-17- and IL-

Lactobacillus pentosus GMNL-77

22-producing CD4þ T cells in the spleen. In conclusion, the present study provides insight

psoriasis

into the potential use of L. pentosus GMNL-77 in the future treatment of psoriasis.

T cells
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Introduction

Psoriasis is a chronic inflammatory skin disorder characterized by epidermal keratinocyte hyperplasia and massive
leukocyte infiltration [1]. It affects approximately 2e3% of the
world population [2]. However, the underlying pathogenic
mechanisms of this condition have not been fully understood.
Recently, numerous studies have confirmed that T helper 17
(Th17) cells and the immune-derived cytokines these cells
produce, including interleukin (IL)-17, IL-22, and IL-23, were
detected in psoriatic skin lesions and serum that were
involved in and interacted as a network in the pathogenesis of
psoriasis [3e10].
Probiotics are defined as “living microorganisms that,
when administered in adequate amounts, confer health benefits to the host” [11]. Most microorganisms identified to date
as probiotics belong to the genera Lactobacillus and Bifidobacterium, which have been extensively studied and
commonly used for centuries in humans and animals. Modulation of the immune system is one of the most plausible
mechanisms underlying the beneficial effects of probiotics on
human health. Probiotics have been found to enhance innate
immunity and modulate pathogen-induced inflammation via
toll-like receptor-regulated signaling pathways [12]. Recent
reports have shown that probiotic use is an effective preventive and therapeutic strategy for different diseases ranging
from allergies to autoimmune diseases. Three interacting
factors, including an aberrant intestinal microflora, a “leaky”
intestinal mucosal barrier, and an altered intestinal immune
responsiveness, have been suggested as being able to create a
“perfect environment” for the development of autoimmune
diseases. In addition to autoimmune diseases, regulation of
the composition of intestinal microbiota by probiotics offers
the possibility of influencing the development of mucosal and
systemic immunity [13]. Probiotics have been reported to be
efficacious against cancers, infections, allergies, inflammatory bowel diseases, and autoimmune diseases and it is
important to explain how such multifunctional activities are
generated. These findings can provide a theoretical basis for
understanding the multifunctional activities of specific probiotics [14].
The actions of probiotics on the skin can be mediated by
the modulation of both the innate and the adaptive immune
responses in the host. Some probiotic strains display potent
immune-modulatory properties in the skin. Recently, the
ability of Lactobacillus paracasei CNCM-I 2116 (ST11) to modulate reactive skin-associated inflammatory mechanisms has
been evaluated. ST11 was able to abrogate vasodilation,
edema, mast cell degranulation, and tumor necrosis factoralpha (TNF-a) release induced by substance P compared with
controls. These results support a beneficial role of ST11 in key
biological processes associated with barrier function and skin
reactivity [15]. Oral administration of Lactobacillus casei can
reduce antigen-specific skin inflammation by controlling the
size of the CD8þ effector pool [16]. Oral administration of heatkilled Lactobacillus sakei proBio65, which are isolated from
Kimchi, inhibited immunoglobulin E-mediated histamine and

b-hexosaminidase release in NC/Nga mice. These results
suggest that dead L. sakei proBio65 has an inhibitory effect on
atopic dermatitis-like skin lesions; it is proposed to be a potential treatment for allergies [17]. In addition, Lactobacillus
acidophilus cultured in a medium of taro waste hydrolysate
showed immune-modulatory effects in luciferase-based nuclear factor-kB and cyclooxygenase-2 systems [18]. Orally
administered L. casei DN-114 001 efficiently alleviates T-cellmediated skin inflammation without causing immune suppression via mechanisms that include the control of CD8þ
effector T cells and the involvement of regulatory CD4þ T cells.
L. casei DN-114 001 may, thus, represent a probiotic of potential interest for the immunomodulation of T-cell-mediated
allergic skin diseases in humans [19].
Experimental data show that the imiquimod (IMQ)induced psoriasis model is highly correlated to human psoriasis lesions with regard not only to the clinical and histological characteristics, but also to the development of the lesions
via the IL-23/IL-17A axis [20]. This study was designed to
investigate the effect of Lactobacillus pentosus GMNL-77 (GMNL77), a potent probiotic strain that is commercially available as
a healthy food product in Taiwan, on an IMQ-induced psoriasis-like mouse model. The effect of GMNL-77 on immune
responses was further investigated.

2.

Methods

2.1.

Mice

Male BALB/c mice (6e8 weeks; 20e25 g) were purchased from
the National Laboratory Animal Center (Nangang District,
Taipei). The mice were housed at the facility of National
Chung Hsing University (South District, Taichung). All experimental animals were used in this study according to a protocol approved by the Institutional Animal Care and Use
Committee of National Chung Hsing University.

2.2.

Bacterial strain, media, and growth conditions

GMNL-77 was obtained from the culture collection of the
GenMont Biotech Incorporation (Shanhua District, Tainan).
GMNL-77 was statically grown in Man Rogosa Sharpe broth
(Difco Laboratories, Detroit, MI, USA) at 37 C for 18 hours,
collected by centrifugation at 3000 g for 5 minutes to remove
the Man Rogosa Sharpe broth, and suspended in sterile water
at a concentration of approximately 2  109 colony-forming
units (CFU)/mL.

2.3.
IMQ-induced psoriasis-like skin inflammation
protocol
After their back skin was shaved, the mice received a topical
application of 62.5 mg IMQ cream (Aldara; 3M Pharmaceuticals, St Paul, MN, USA) daily for 6 consecutive days. For the
GMNL-77 treatment, the mice were fed orally with different
doses of GMNL-77 (5  107 CFU/0.2 mL/d or 5  108 CFU/0.2 mL/
d) or with the vehicle control (distilled water) for 7 consecutive
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days, starting from 1 day before IMQ administration. The
severity of inflammation of the back skin was evaluated using
a modified target lesion psoriasis severity scoring system.
Mice were monitored and graded daily with respect to back
redness (erythema) and the presence of scales (scaling), on a
scale from 0 (no alteration) to 4 (very distinct alteration).

isothiocyanate (FITC)-conjugated mAbs specific to murine IL17A (TC11-18H10.1) and IL-22 (Poly5164), purchased from
BioLegend. The stained cells were acquired on a BD Accuri C5
cytometer Cat. No. 657214 (BD Biosciences, San Jose, CA, USA)
and analyzed with BD Accuri C6 software, version 1.0264.21.

2.4.

2.7.

Skin histology

On Experimental Day 6, the skin samples from the
lesions of mice were fixed in 4% formaldehyde
embedded in paraffin. Deparaffinized sections (6 mm)
stained with hematoxylin and eosin to study
microarchitecture.

back
and
were
their

2.5.
Quantitative reverse transcriptase polymerase
chain reaction
At 72 hours after starting the experiment, total RNA was
extracted from the back skin lesions using the TRIzol (Invitrogen, Carlsbad, CA, USA), and complementary DNA was
generated using a Transcriptor First Strand cDNA Synthesis
Kit (Roche, West Sussex, UK). The relative express levels of
genes were assessed using SYBR Green Master Mix (Roche,
West Sussex, UK) with the following primers: TNF-a, F: 50 GGCTGCCCCGACTACGT-30 and R: 50 -CTCCTGTGGTATGAGATAGCAAATC-3; IL-6, F: 50 -TGCCATTGCACAACTCTTTTCT-30
and R: 50 -TCGGAGGCTTAATTACACATGTTC-30 ; IL-23, F: 50 and R: 50 -CGGA
GTATCCAGTGTGAAGATGGTTGTGA-30
TCCTTTGCAAGCAGAA-30 ; IL-17A, F: 50 -TTTTCAGCAAGGAATGTGGA-30 and R: 50 -TTCATTGTGGAGGGCAGAC-30 ; IL17F, F: 50 -GAGGATAACACTGTGAGAGTTGAC-30 and R: 50 GAGTTCATGGTGCTGTCTTCC-30 ; IL-22, F: 50 -GAAGGCTGAAGGAGACAGTGAAA-30 and R: 50 -GTTCCCCAATCGCCTTGA-30 ;
hypoxanthine guanine phosphoribosyl transferase 1 (HPRT), F:
50 -GTTGGATAAGGCCAGACTTTGTTG-30 and R: 50 -GATTCAACTTGCGCCATCTTAGGC-3; in Eco Real-Time PCR System
(Illumina, San Diego, CA, USA). The HPRT gene was used as a
reference to normalize the data. The relative expression level
of the gene in the experimental group was compared with that
of the water-treated mouse group.

2.6.

Flow cytometry analysis

On Experimental Day 6, spleen cells of each group of mice
were weighed with an electronic balance and were then
extracted via mechanical disruption using 30 mm steel mesh
screens in a fresh Petri dish to prepare single-cell suspensions.
For intracellular detection of cytokines, 2  105 cells/well were
stimulated with plate-bound anti-CD3 mAb [clone 145-2C11
(BD Pharmingen, Oxford, UK); 5 mg/mL] and soluble anti-CD28
(1 mg/mL) for 24 hours. Golgistop solution (BD Biosciences, San
Diego, CA, USA) was put into the culture 4 hours before cell
harvesting. The cells were then stained with phycoerythrinconjugated antimouse CD4 (GK1.5; BioLegend), followed by
treatment with Cytofix/Cytoperm Plus Kit (BD Biosciences)
according to the manufacturer's instructions (BD Biosciences).
Cells were then stained intracellularly using the fluorescein

Statistical analysis

The data were expressed as mean ± standard deviation. Statistical significance between groups was compared using the
ManneWhitney U test compared with water-treated IMQ
control. All the statistical analyses were performed using
GraphPad Prism software package, version 5.0 (GraphPad
Software, San Diego, CA, USA). Significance was assigned at
p < 0.05.

3.

Results

3.1.
GMNL-77 alleviates skin lesions in IMQ-induced
psoriasis-like mice erythema (0.80 ± 0.40, p < 0.05) and
scaling (0.75 ± 0.33, p < 0.05)
As shown in Figures 1A and 1B, mice developed apparent
psoriasis-like lesions, including erythema and scaling of the
lesion skin, after treatment with IMQ for 6 consecutive days.
Meanwhile, mice fed 5  108 CFU/d of GMNL-77 showed
significantly reduced lesions in the IMQ-treated group
(p < 0.05) (Figures 1A and 1B). The erythema and scaling scores
of the GMNL-77 (5  108 CFU/d) group were 2.13- and 2.26-fold
less than the IMQ group at the end of the experiment. To
further analyze the effects of GMNL-77, histological (hematoxylin and eosin) staining was also carried out on the skin
lesions in mice on Day 6. The results showed that the
epidermal thickness significantly increased in the IMQtreated skin as a result of hyperproliferation of keratinocytes. However, a high dose of GMNL-77 (5  108 CFU/d)
reduced the IMQ treatment-induced thickness of the
epidermal tissue.

3.2.
GMNL-77 suppresses inflammatory cytokines in the
skin lesions of IMQ-treated mice
Recently, cytokines have also been found to be involved in the
induction of IMQ-induced psoriasis-like inflammation
[3,20e24]. Cytokines play important physiological and pathological roles in many diseases [25]. Therefore, to further
explore whether GMNL-77 inhibits proinflammatory and
Th17-associated cytokine production, we analyzed these
psoriasis-related cytokine profiles in the skin lesions using
quantitative reverse transcriptase polymerase chain reaction
analysis. As shown in Figure 2, the levels of TNF-a (6.50 ± 2.38,
p < 0.05), IL-6 (0.81 ± 0.59, p < 0.05), IL-23 (1.77 ± 0.78, p < 0.05),
IL-17A (1.13 ± 0.61, p < 0.05), IL-17F (2.93 ± 1.67, p < 0.05), and IL22 (4.55 ± 1.11, p < 0.05) were significantly reduced when mice
were treated with a high dose of GMNL-77 (5  108 CFU/d).
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Figure 1 e GMNL-77 reduced psoriasis-like skin inflammation. (A) Phonotypical presentation of the effects of oral
administration of GMNL-77 on IMQ-induced psoriasis-like skin lesions after 6 days of treatment. (B) Erythema and
scaling of back skin scored daily on a scale from 0 to 4. Symbols represent mean score ± SD of six mice per group. Data
shown are representative of three experiments. (C) Representative photomicrographs of hematoxylin and eosin-stained
section of back skin tissue of the experimental mice. * p < 0.05 (ManneWhitney U test) versus IMQ/water control group.
GMNL-77 ¼ L. pentosus GMNL-77; IMQ ¼ imiquimod; SD ¼ standard deviation.
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Figure 2 e GMNL-77 reduced mRNA levels of skin inflammatory cytokines and IL-23/IL-17-associated cytokines in the back
skin induced by IMQ. Skin was excised from different treatment groups at 72 hours, and RNA was extracted to analyze
mRNA expression of TNF-a, IL-6, IL-23, IL-17A, IL-17F, and IL-22 by real-time RT-PCR. The HPRT gene was used as a
reference to normalize the data. The relative expression level of the gene in the experimental group was compared with that
of the water-treated mouse group. Data on the graph represents the mean ± SD, with six mice per group. Data shown are
representative of three experiments. * p < 0.05 (ManneWhitney U test) versus IMQ/water control group. GMNL-77 ¼ L.
pentosus GMNL-77; HPRT ¼ hypoxanthine guanine phosphoribosyl transferase 1; IL ¼ interleukin; IMQ ¼ imiquimod;
ns ¼ not significant; RT-PCR ¼ reverse transcriptase polymerase chain reaction; SD ¼ standard deviation; TNF-a ¼ tumor
necrosis factor-alpha.

3.3.
GMNL-77 reduces the number of Th17/Th22 T cells
in the spleen of IMQ-treated mice
To further determine whether orally administered L. pentosus
can affect systemic immune responses, we initially examined
the spleen weights on Day 6 after IMQ treatment (Figure 3).
IMQ was previously found to induce splenomegaly through
systemic effects [20]. In this study, our data identified a
consistently significant spleen enlargement following 6 days
of IMQ treatment in mice. However, the average spleen
weights of the mice in the IMQ-treated-group were reduced
after these mice were fed with 5  108 CFU/d of GMNL-77
(399.8 ± 81.8 vs. 176.5 ± 43.0, p < 0.05) (Figure 4A).
By contrast, in several different chronic inflammatory
conditions including psoriasis, IL-17 and IL-22 are secreted by
CD4þ [20,26]. Therefore, we determined the effect of GMNL-77
on IL-17 and IL-22 production by CD4þ T cells in the spleen.
Splenic cells were activated ex vivo by anti-CD3þ plus antiCD28 Ab, stained intracellularly for IL-17 or IL-22 in gated

CD4þ T cells and analyzed using flow cytometry. As shown in
Figure 4B, the numbers of IL-17A-producing CD4þ T cells
(Th17) and IL-22-producing CD4þ T cells (Th22) were increased
following IMQ treatment. However, the percentages of Th17
and Th22 cells in the spleens of the GMNL-77 (5  108 CFU/d)fed group were significantly lower than those of the IMQtreated control group (Figure 4B). These results imply that
GMNL-77 reduces the differentiation of CD4þ T cells to inhibit
the systemic inflammatory response following IMQ
treatment.

4.

Discussion

IMQ, a kind of immunomodulating drug, was first approved by
FDA for the topical treatment of external genital and perianal
warts in 1997, and now is also used to treat superficial basal
cell carcinoma and actinic keratosis [27e29]. However, IMQ
may cause certain side effects related to inflammation, such
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Figure 3 e GMNL-77 reduced the size and weight of the spleen induced by IMQ. (A) Mice were sacrificed on Day 6, size of
spleens with comparison in representative images direct-viewing. (B) The spleens were weighed when the mice were
sacrificed. The bar graphs represent the mean ± SD, with six mice per group. Data shown are representative of three
experiments. * p < 0.05 (ManneWhitney U test) versus IMQ/water control group. GMNL-77 ¼ L. pentosus GMNL-77;
IMQ ¼ imiquimod; SD ¼ standard deviation.

as blisters, burning sensation, skin redness, skin flaking, or
scaling. It has been reported that IMQ-induced skin inflammation of mice can be utilized as a model of human psoriatic
lesions that exhibit similar phenotypic and histological characteristics, including erythema, epidermal thickening,
scaling, and neoangiogenesis, as well as the inflammatory
infiltrates of T cells, neutrophils, and dendritic cells [30]. In the
present study, we investigated the effect of L. pentosus on skin
lesions in IMQ-induced psoriasis-like mice model.
L. pentosus is a versatile lactic acid bacterium found in
various environmental niches and in the gastrointestinal
tract. It is widely used in the production of fermented foods,
such as milk, breads, and vegetables, especially table olives
[31]. Specific L. pentosus strains have been shown to elicit
probiotic effects, including modulation of the intestinal
microbiota [32], inhibition of bacterial and viral pathogens
[33], and regulation of the host immune response [34]. In this
study, GMNL-77 appears to inhibit IMQ-induced psoriasis-like
inflammation in the skin of IMQ-treated mice based on the
following roles of GMNL-77: (1) decreased skin erythema and
scaling; (2) inhibited hyperplastic basal suprabasal keratinocytes; (3) suppressed mRNA expression of proinflammatory
cytokines, including TNF-a, IL-6, and the IL-23eIL-17 cytokine
axis (IL-23, IL-17A/F, IL-22) in skin lesions; (4) decreased the
spleen weights; and (v) reduced the numbers of IL-17/IL-22producing CD4þ T cells in the spleen of the IMQ-treated mice.
For the systemic action of IMQ, several weeks of topical
treatment leads to psoriasis lesions, a severe side effect, not
only at the site of application, but also at inaccessible sites
[28,29]. The IMQ-induced skin inflammation model in mice
helps illustrate this appearance. We found significant
splenomegaly in IMQ-treated mice at the end of the

experiment, and the spleen weight increased approximately
threefold when compared with the naive group. The spleen is
the largest immune organ reflecting systemic immune status
in the human body and plays an important role in antiinfection and anticancer activities since it possesses various
immunocompetent cytokines [35]. It is suggested that the
increased spleen mass observed in the IMQ-induced psoriasislike mice is due to a large increase in the number of cells in the
spleen and may be a sign of increasing the immunoreaction in
the body [30]. Enhancement of Th17/Th22 T cells in the spleen
of IMQ-treated mice was confirmed in the present study. Oral
administration of GMNL-77 (5  108 CFU/d) significantly
reduced spleen mass in IMQ-treated mice, which suggests
that GMNL-77 can decrease the number of Th17/Th22 T cells
of the spleen and alleviate the inflammatory response.
Recent studies have demonstrated that IL-17- and IL-22producing Th17 and Th22 cells serve as models for analyzing
the pathogenic mechanisms associated with psoriasis-like
dermatitis [21,22,36,37]. First, the results of the present study
show that GMNL-77 can decrease the percentage of IL-17Aand IL-22-producing CD4þ T cells in the IMQ-treated mice
(Figure 4). Although the mechanism for GMNL-77-suppressing
T-cell activity in vivo is unclear, we propose the following two
possibilities: (1) GMNL-77 may decrease the activity of the
intestinal antigen-presenting cells, such as the CD103þ dendritic cells, which have been shown to play a critical role in
modulating Tregs in the gastrointestinal tract, thus affecting
cell proliferation or differentiation; and (2) GMNL-77 has a
direct effect on the molecular mechanisms of the differentiation or proliferation of T cells.
In summary, we demonstrate that oral administration of
GMNL-77 is an effective remedy for treating psoriasis in a
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Figure 4 e GMNL-77 decreased the numbers of Th17 and Th22 cells of the mice spleen induced by IMQ treatment. Mice were
sacrificed on Day 6, spleen cells were isolated, and in vitro stimulated for 24 hours by plate-bound anti-CD3 and anti-CD28
Ab. Data from flow cytometry were analyzed for the number of IL-17A þ CD4 þ Th17 and IL-22 þ CD4 þ Th22 cells. (A) The
dot plots show data from one representative mouse of each group. (B) The bar graphs represent the mean ± SD with six mice
per group. Data shown are representative of three experiments. * p < 0.05 (ManneWhitney U test) versus IMQ/water control
group. GMNL-77 ¼ L. pentosus GMNL-77; IL ¼ interleukin; IMQ ¼ imiquimod; SD ¼ standard deviation; Th ¼ T helper cells.

mouse model. These effects were the result of inhibiting the
differentiation and proliferation of keratinocytes reducing the
levels of skin inflammatory cytokines and the differentiation
of IL-17/IL-22-producing CD4þ T cells in the spleen. Data obtained from these studies are encouraging; however, the
molecular and cellular mechanisms responsible for the multiple effects of GMNL-77, such as anti-inflammatory factor
expression and the search for a new and efficient element to
dampen the inflammation process, require further
investigation.

Conflicts of interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This work was supported by the GenMont Biotech Incorporation. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the
manuscript.

references

€ n MP, Boehncke WH. Psoriasis. N Engl J Med
[1] Scho
2005;352:1899e912.
[2] Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E.
Psoriasis: what we have learned from mouse models. Nat
Rev Rheumatol 2010;6:704e14.

566

j o u r n a l o f f o o d a n d d r u g a n a l y s i s 2 5 ( 2 0 1 7 ) 5 5 9 e5 6 6

[3] El Malki K, Karbach SH, Huppert J, Zayoud M, Reisig S,
Schuler R, Nikolaev A, Karram K, Munzel T, Kuhlmann CRW,
Luhmann HJ, von Stebut E, Wortge S, Kurschus FC,
Waisman A. An alternative pathway of imiquimod-induced
psoriasis-like skin inflammation in the absence of
interleukin-17 receptor a signaling. J Invest Dermatol
2013;133:441e51.
[4] Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating
Th17, Th22, and Th1 cells are increased in psoriasis. J Invest
Dermatol 2010;130:1373e83.
[5] Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS,
Sandoval L, Feldman SR. Interleukin-23 and interleukin-17:
importance in pathogenesis and therapy of psoriasis.
Dermatol Online J 2012;18:1.
[6] Res PC, Piskin G, de Boer OJ, van der Loos CM, Teeling P,
Bos JD, Teunissen MB. Overrepresentation of IL-17A and IL22 producing CD8 T cells in lesional skin suggests their
involvement in the pathogenesis of psoriasis. PLoS One
2010;5:e14108.
[7] Tokura Y. Th17 cells and skin diseases. Nihon Rinsho Meneki
Gakkai Kaishi 2012;35:388e92 [In Japanese].
[8] Wang WJ, Yin XY, Zuo XB, Cheng H, Du WD, Zhang FY,
Yang S, Zhang XJ. Geneegene interactions in IL23/Th17
pathway contribute to psoriasis susceptibility in Chinese
Han population. J Eur Acad Dermatol Venereol
2013;27:1156e62.
[9] Yoo IS, Lee JH, Song ST, Kim JH, Lee HJ, Kang SW. T-helper 17
cells: the driving force of psoriasis and psoriatic arthritis. Int
J Rheum Dis 2012;15:531e7.
[10] Zhang L, Yang XQ, Cheng J, Hui RS, Gao TW. Increased Th17
cells are accompanied by FoxP3(þ) Treg cell accumulation
and correlated with psoriasis disease severity. Clin Immunol
2010;135:108e17.
[11] Joint FAO/WHO Expert Committee on Food Additives. and
World Health Organization. Food & Agriculture Organization.
Safety evaluation of certain mycotoxins in food. Issue 74.
Meeting, 2001.
[12] Yan F, Polk DB. Probiotics and immune health. Curr Opin
Gastroenterol 2011;27:496e501.
€
€ Any role for probiotics in the therapy or
[13] Ozdemir
O.
prevention of autoimmune diseases? Up-to-date review. J
Complement Integr Med 2013;10:229e50.
[14] Shida K, Nanno M, Nagata S. Flexible cytokine production by
macrophages and T cells in response to probiotic bacteria: a
possible mechanism by which probiotics exert
multifunctional immune regulatory activities. Gut Microbes
2011;2:109e14.
[15] Gueniche A, Benyacoub J, Philippe D, Bastien P, Kusy N,
Breton L, Blum S, Castiel-Higounenc I. Lactobacillus paracasei
CNCM I-2116 (ST11) inhibits substance P-induced skin
inflammation and accelerates skin barrier function recovery
in vitro. Eur J Dermatol 2010;20:731e7.
[16] Chapat L, Chemin K, Dubois B, Bourdet-Sicard R,
Kaiserlian D. Lactobacillus casei reduces CD8þ T cell-mediated
skin inflammation. Eur J Immunol 2004;34:2520e8.
[17] Kim JY, Pyo S. Oral administration of dead Lactobacillus sakei
inhibits atopic dermatitis-like skin lesion in NC/Nga mice.
FASEB J 2012;26:lb364.
[18] Hsieh SC, Liu JM, Pua XH, Ting Y, Hsu RJ, Cheng KC.
Optimization of Lactobacillus acidophilus cultivation using taro
waste and evaluation of its biological activity. Appl Microb
Biotechnol 2016;100:2629e39.
[19] Hacini-Rachinel F, Gheit H, Le Luduec JB, Dif F, Nancey S,
Kaiserlian D. Oral probiotic control skin inflammation by
acting on both effector and regulatory T cells. PLoS One
2009;4:e4903.

[20] van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L,
Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP,
Lubberts E. Imiquimod-induced psoriasis-like skin
inflammation in mice is mediated via the IL-23/IL-17 axis. J
Immunol 2009;182:5836e45.
[21] Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I,
Zaba LC, Haider AS, Bowman EP, Krueger JG. Psoriasis
vulgaris lesions contain discrete populations of Th1 and
Th17 T cells. J Invest Dermatol 2008;128:1207e11.
[22] Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE,
Krueger JG, Russell CB. The emerging role of IL-17 in the
pathogenesis of psoriasis: preclinical and clinical findings. J
Invest Dermatol 2013;133:17e26.
[23] Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med
2009;361:496e509.
[24] Flutter B, Nestle FO. TLRs to cytokines: mechanistic insights
from the imiquimod mouse model of psoriasis. Eur J
Immunol 2013;43:3138e46.
[25] Sun Y, Shao Y, Zhang Z, Wang L, Mariga AM, Pang G, Geng C,
Ho CT, Hu Q, Zhao L. Regulation of human cytokines by
Cordyceps militaris. J Food Drug Anal 2014;22:463e7.
[26] Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL. gd
T cells: an important source of IL-17. Curr Opin Immunol
2008;20:353e7.
[27] Lacarrubba F, Nasca MR, Micali G. Advances in the use of
topical imiquimod to treat dermatologic disorders. Ther Clin
Risk Manag 2008;4:87e97.
[28] Rajan N, Langtry JA. Generalized exacerbation of psoriasis
associated with imiquimod cream treatment of superficial
basal cell carcinomas. Clin Exp Dermatol 2006;31:140e1.
[29] Fanti PA, Dika E, Vaccari S, Miscial C, Varotti C. Generalized
psoriasis induced by topical treatment of actinic keratosis
with imiquimod. Int J Dermatol 2006;45:1464e5.
[30] Qin S, Wen J, Bai XC, Chen TY, Zheng RC, Zhou GB, Ma J,
Feng JY, Zhong BL, Li YM. Endogenous n-3 polyunsaturated
fatty acids protect against imiquimod-induced psoriasis-like
inflammation via the IL-17/IL-23 axis. Mol Med Rep
2014;9:2097e104.
s N. Lactic acid
[31] Hurtado A, Reguant C, Bordons A, Roze
bacteria from fermented table olives. Food Microbiol
2012;31:1e8.
[32] Siggers RH, Siggers J, Boye M, Thymann T, Mølbak L, Leser T,
Jensen BB, Sangild PT. Early administration of probiotics
alters bacterial colonization and limits diet-induced gut
dysfunction and severity of necrotizing enterocolitis in
preterm pigs. J Nutr 2008;138:1437e44.
[33] Izumo T, Maekawa T, Ida M, Noguchi A, Kitagawa Y,
Shibata H, Yasui H, Kiso Y. Effect of intranasal
administration of Lactobacillus pentosus S-PT84 on influenza
virus infection in mice. Int Immunopharmacol
2010;10:1101e6.
[34] Nonaka Y, Izumo T, Izumi F, Maekawa T, Shibata H,
Nakano A, Kishi A, Akatani K, Kiso Y. Antiallergic effects of
Lactobacillus pentosus strain S-PT84 mediated by modulation
of Th1/Th2 immunobalance and induction of IL-10
production. Int Arch Allergy Immunol 2008;145:249e57.
[35] Liu CJ, Lin JY. Protective effects of strawberry and mulberry
fruit polysaccharides on inflammation and apoptosis in
murine primary splenocytes. J Food Drug Anal 2014;22:210e9.
[36] Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL,
Blauvelt A. IL-23-mediated psoriasis-like epidermal
hyperplasia is dependent on IL-17A. J Immunol
2011;186:1495e502.
[37] SchOn MP, Detmar M, Parker CM. Murine psoriasis-like
disorder induced by naive CD4þ T cells. Nat Med
1997;3:183e8.

